Evidence map›Paper›PMID 41257949›Full record

ReviewJournal of ovarian research2025

Genome doubling as a dynamic driver of ovarian cancer evolution: insights from single-cell sequencing.

Tianjiao Zhao, Tianshi Zhao, Dengyu Dong, Dengyue Dong

Abstract readReview
In one paragraph

Review in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tianjiao ZhaoClinical School, North Henan Medical University, Xinxiang, Henan, 453003, China. tian.jiao.856@163.com.
Tianshi ZhaoDepartment of Basic Medicine, Zhengzhou Health Vocational College, Zhengzhou, 450000, Henan, China. 17719947127@163.com.
Dengyu DongSchool of Education, University of Glasgow, G128QQ, Glasgow, Scotland.
Dengyue DongSchool of Business, Shang- hai Normal Univesi- ty Tianhua college, Shanghai, 201815, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whole-genome doubling (WGD) is a macro-evolutionary event that is both prevalent and prognostically significant in human cancers, particularly in high-grade serous ovarian carcinoma (HGSOC). Historically, WGD has been viewed as a consequence of widespread genomic instability, but recent advancements in single-cell sequencing (sc-seq) have reframed its role as a central, dynamic driver of tumor evolution. This review summarizes cutting-edge findings, demonstrating how WGD acts as a catalyst for a distinct evolutionary trajectory characterized by the rapid accumulation of chromosomal losses and the selection of highly adaptable clones. A key finding is the resolution of a biological paradox: WGD-driven chromosomal instability, which should provoke an immune response, is instead correlated with a profoundly immunosuppressive phenotype via the repression of key innate immune pathways. Finally, this review discusses the clinical implications of these discoveries, highlighting WGD's potential as a predictive biomarker and a source of unique therapeutic vulnerabilities, paving the way for targeted strategies in advanced HGSOC.

Indexed as

Genome, HumanOvarian NeoplasmsSingle-Cell AnalysisFemaleGenomic InstabilityHumansChromosomal instabilityHigh-grade serous ovarian carcinomaImmunosuppressionTumor evolutionWhole-genome doubling

Identifiers

PMID41257949
PMCPMC12628590

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.